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Abstract
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B-1 cells reside predominantly within the coelomic cavities, tonsils, Peyer’s patches, spleen (a minor
fraction – ∼5%) and are absent in the lymph nodes. They are the primary sources of natural IgM in
the body. B-1 cells express polyreactive B cell receptors (BCR) that cross react with self antigens
and thus implicated in auto-immune disorders. Previously, we reported that peritoneal B-1 cells are
deficient in CD19-mediated intracellular signals leading to Ca2+ mobilization. Here, we find that
splenic B-1 cells, like peritoneal B-1 cells, are defective in Ca2+ release upon B cell activation by
co-cross-linking BCR and CD19. In the absence of extracellular sources of Ca2+, intracellular
Ca2+ flux is similar between B-1 and B-2 cells. Moreover, the intracellular component of Ca2+ release
in both subsets of B cells is mostly PI3K dependent. BCR and CD19 co-cross-linking activates Akt,
a key mediator of survival and proliferation signals downstream of PI3K in splenic B-2 cells. Splenic
B-1 cells, on the other hand, do not phosphorylate Akt (S473) upon similar treatment. Furthermore,
BCR + CD19 cross-linking induced phosphorylation of JNK is much reduced in splenic B-1 cells.
In contrast, B-1 cells exhibited increased levels of constitutively active pLyn which appears to have
an inhibitory role. The CD19 induced Ca2+ response and BCR induced proliferation response were
restored by a partial inhibition of pLyn with Src kinase specific inhibitors. These findings suggest a
defect in CD19 mediated signals in both peritoneal and splenic B-1 B lymphocytes, which is in part,
due to higher levels of constitutively active Lyn.
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B-1 cells are distinguished from B-2 cells based on their anatomical localization, cell surface
phenotype, self-renewal capacity, B cell receptor signal generation, and contribution to natural
circulating serum IgM (Berland and Wortis, 2002; Hayakawa et al., 1985; Hayakawa et al.,
1984; Hayakawa et al., 1986). B-1 cells are localized in the coelomic cavities (peritoneal and
pleural), Peyer’s patches, tonsils, and spleen (~5% of splenic B cells) and absent in lymph
nodes. B cell activation initiates a cascade of intracellular signaling events leading to cell
proliferation, differentiation and secretion of the antibody or apoptosis. Binding of antigen or
its surrogate, anti-IgM leads to clonal expansion in the follicular (FO) or the ‘conventional’
B-2 B cells. Unlike B-2 cells, B-1 cells are hyporesponsive to BCR cross-linking and share
some similarities with anergic cells (Hippen et al., 2000). Paradoxically, B-1 cell numbers are
increased in several murine models of autoimmune disorders, such as NZB, MRL/lpr and
motheaten mice, as well as in humans with lupus or rheumatoid arthritis (Burastero et al.,
1988; Dauphinee et al., 1988; Hayakawa et al., 1983; Mohan et al., 1998; Sidman et al.,
1986). In blood, rheumatoid factor producing B cells were found to be predominantly B-1 type
(Haas et al., 2005; Hardy et al., 1987).
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B-1 cells are further subdivided into B-1a and B-1b subtypes as the former but not the latter
express CD5 (Stall et al., 1992). Bikah et al. have established that CD5 antigen on B-1a cells
inhibits signaling through the B cell receptor (Bikah et al., 1996). Sen et al. showed that CD5
down regulates BCR signaling by recruiting SHP-1 (Src homology 2 (SH2) domain containing
protein tyrosine phosphatase-1) into the BCR complex (Sen et al., 1999). More recently, Dal
Porto et al. showed that CD5 may induce activation of Lck which may in turn inhibit BCR
signaling in B-1 cells (Dal Porto et al., 2004). This, however, is controversial since Frances et
al. showed that B-1 cells do no express Lck (Frances et al., 2005). We have shown that FACS
sorted peritoneal B-1a and B-1b B cells are equally defective in BCR induced proliferative
response (Sen et al., 2002). B-1a and B-1b B cells collaborated in immunity to S.
pneumoniae by respectively contributing to innate and adaptive immune responses (Haas et
al., 2005). Since B-1b cells do not express CD5, the basis of BCR signaling defect is unclear.
Recently, it has been shown that B-1b B cells may be primarily responsible for IgM memory
cells, as they were expanded preferentially in a murine model of relapsing fever (Alugupalli
et al., 2004). B-1b B cells have thus gained attention as crucial players of cell mediated antibody
responses independent of T cell help (Alugupalli, 2008). Recent description of IL-10 producing
splenic CD1dhi CD5+ B cells in mice with a regulatory role reinforces the importance of B-1
B cells in T-cell mediated immunity (Yanaba et al., 2008). These regulatory B cells (Breg) are
proposed to suppress activation and differentiation of CD4+, CD8+, NKT and other immune
cell types thereby demanding caution in B cell depletion therapeutics as it may hinder
maintenance of tolerance (Mauri and Ehrenstein, 2008).
The B cell restricted glycoprotein CD19 in concert with CD21/CR2 and CD81/TAPA-1 forms
a co-receptor complex and aids in BCR function as a positive regulator of B cell signaling by
lowering the threshold for B cell activation (Carter and Fearon, 1992). Activation of CD19 is
dependent upon Lyn-mediated phosphorylation of CD19 cytoplasmic domain (Fujimoto et al.,
2001). There are 9 conserved tyrosine residues on CD19 cytoplasmic tail that upon
phosphorylation allow recruitment of adaptor molecules such as Grb2, Sos, Vav and activation
of PLCγ, Fyn, Lyn and PI3K (Wang et al., 2002). These molecules are responsible for
downstream signaling events leading to calcium (Ca2+) mobilization, mitogen activated protein
kinase (MAPK) activation and induction of transcription factors. We had previously reported
that peritoneal B-1a and B-1b B cells are defective in CD19-dependent signaling events and
speculated on the possible candidates that are differently regulated in B-1 versus B-2 cells
(Sen et al., 2002).
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Recently it has been proposed that splenic B-1 cells are distinct from peritoneal B-1 cells since
the latter but not the former express constitutively activated form of STAT-3 (Fischer et al.,
2001). Moreover, peritoneal but not splenic B-1 cells responded to stimulation with PMA alone.
Hence we attempted to perform a comprehensive study of CD19 signaling in B-1a and B-1b
B cells from both peritoneal and spleen of wild type mice. Additionally, we utilized splenic
B-1 cells from VH12 transgenic mice to determine the biochemical basis of CD19 dependent
signaling in B-1 cells (Arnold et al., 1994). We show that the positive signaling role of CD19
is defective in all B-1 cell subsets (B-1a and B-1b from both spleen and peritoneum) examined.
Biochemically, this resulted in a lack of activation of JNK and Akt, key enzymes required for
B cell survival and proliferation. Here, we demonstrate that B-1 cells have elevated levels of
constitutively active Lyn and that it plays a role in the negative regulation of BCR and CD19
signaling.

MATERIALS AND METHODS
Mice
8–16 week old female C57BL/6 mice were obtained from the Jackson Laboratories (Bar
Harbor, MA). VH12 transgenic mice in the C.B-17 background were described by Arnold et
al. and were kept in heterozygous state by crossing to C.B-17 mice (Arnold et al., 1994). The
PCR screened negative littermates were used as control mice.
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Purification of B cells
3–4 month old female C57BL/6 mice were used to obtain peritoneal cells by peritoneal lavage
with Hank’s balanced salt solution. For in vitro proliferation assays with peritoneal and splenic
B cells, macrophages were removed by short-term plastic adherence and T cells were depleted
using an antibody cocktail with anti-Thy 1.2, anti-CD4 (L3T4) and anti-CD8 (Lyt2) followed
by rabbit complement, as described earlier (Sen et al., 2002). Anti-B220/CD45RB~FITC, antiCD23~PE or anti-CD43~FITC (BD Pharmingen, San Jose, CA) were used to identify and sort
B-2 (B220+ CD43−) and B-1 (B220+ CD43+) cells from splenic populations of C57BL/6 or
VH12 transgenic mice (Wells et al., 1994).
In vitro cell proliferation assay
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Splenic B-2 or B-1 and peritoneal B-1 cells were cultured in IF-12 medium (with 10% FBS).
Cells plated at 2.5 × 105 cells/well were stimulated with 50 μg/ml polyclonal goat anti-IgM F
(ab′)2 (ICN/MP Biomedicals, Irvine, CA), 1 μg/ml LPS (Sigma, St. Louis, MO) and 1:1000
anti-CD40 (1C10) ascites (Heath et al. 1994). Cultures were pulsed with 3[H] Thymidine
(DuPont/NEN) on day 2 for 4 hours, harvested (Packard, Meriden, CT) and the incorporated
radioactivity was measured using a Matrix 96 β-counter (Packard, Downers Grove, IL). Results
are represented as mean + SE of triplicate cultures.
Calcium release analysis
10 × 106 splenic cells were loaded with 1 μM Indo-1 AM (Molecular Probes Inc., Eugene, OR)
at 37°C for 30 min. Cells were then stained with anti-B220~PE and anti-CD43~FITC on ice
for 30 min along with biotinylated goat anti-mouse IgM F (ab′)2 (MP Biomedicals, Irvine, CA)
and anti-CD19 (1D3) antibodies, washed and resuspended in insulin and progesterone free
IF-12 media (10% FBS). Two minutes before analysis, the cells were resuspended in
prewarmed media (6 mM EGTA containing media was used for intracellular Ca2+ release
study) and a baseline calcium release was measured for 30 s. Then, avidin (Sigma, St. Louis,
MO) was added to the cell suspension and calcium levels were measured for 5 min. The ratio
of fluorescence (405/545 nm) of the gated B-2 and B-1 cells was determined using the MoFlo
cytometer (Dako Cytomation Inc., Fort Collins, CO) and analyzed using the Summit software
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program. An increase in the ratio of violet to blue fluorescence indicates an increase in Ca2+
concentration in the cell. Cells from peritoneal lavage were treated similar to splenic cells.
They were, however, stained with α-B220~CY, α-Mac-1~PE and α-CD5~FITC for
distinguishing B-1a, B-1b and B-2 subsets. To determine the importance of PI3K, B cells were
pre-incubated with Wortmannin for 25 min at room temperature. 6 mM EGTA containing
media was used to determine the effect of CD19 signaling on intracellular calcium release. 2
μM Thapsigargin (Molecular Probes Inc., Eugene, OR) was added after obtaining a 30 s Indo-1
baseline. Experiments with PP1 and PP2 (Biomol International, L.P., Plymouth Meeting, PA)
were performed by addition of the inhibitor to cells at room temperature for 20–40 min prior
to 37°C pre-warming for 2 min.
B cell stimulation and Immunoblotting
5–10 × 106 splenic B cells were initially allowed to rest for 3–4 h in serum free IF-12 at 37°
C. Appropriate stimulations were performed for indicated periods of time while incubating in
a 37°C water bath. Reactions were stopped with addition of cold PBS, pH 7.2, containing
10mM NaF and 1mM Na3VO4. After two washes with stop buffer, cell pellet was lysed in 1%
NP-40 cell lysis buffer containing 10 μg/ml Aprotinin, 10 mM PMSF, 1 mM Leupeptin for 30
min on ice. Lysates were cleared of nuclear debris by centrifugation at 10,000 rpm for 10 min
at 4°C. Wherever indicated, 2 μM PP1 was added to cell suspension and incubated at 37° C
for 30 min prior to addition of stimulating antibodies.
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Proteins were denatured by boiling for 5–10 min in Laemmli’s reducing sample buffer and
separated on 10% SDS-PAGE gels. Separated proteins were transferred to PVDF membrane
(Immobilon-P transfer membrane, Millipore Corporation, Billerica, MA). Membranes were
blocked with 1% BSA (for phospho-antibodies) or 5% milk in TBS containing 0.05%
Tween-20 for an hour at room temperature. The blots were probed with primary (1 hr or
overnight) and secondary (HRP conjugated) antibodies (1hr at room temperature) followed by
developing in SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockfold, IL) for
a minute. Protein bands were visualized on the Kodak Image Station 200RT (Eastman Kodak
Company, New Haven, CT) and quantified according to the manufacturer’s software.
Alternatively, the membrane was exposed to BioMax XAR Film (Eastman Kodak Company,
Rochester, NY) and the bands were quantified using Scion Image software. Fold induction of
bands specified was calculated by dividing the mean band intensities of protein of interest to
the appropriate loading control and normalizing the media control group as 1.0.
Reagents
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Rabbit polyclonal antibodies to pJNK, pAkt (S473), Akt and pSrc (Y416) were purchased from
Cell Signaling Technology (Beverly, MA); monoclonal anti-mouse β-actin was from SigmaAldrich (St. Louis, MO). Anti-JNK1, anti-SHP-1, anti-Lyn and secondary reagents were
obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Statistics
Student’s t test was used to determine statistical significance of differences between various
groups.

RESULTS
Splenic B-1 cells are hyporesponsive to BCR induced proliferation
B cell receptor cross-linking of splenic B-2 cells leads to clonal expansion as observed by the
vigorous proliferation of these cells. Peritoneal B-1 cells, on the other hand, do not mount a
proliferative response to anti-IgM stimulation (Bikah et al., 1996). Because of the recent studies
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on differential role of B-1a and B-1b B cells in immune responses to Borrelia hermsii and S.
penumoniae and reported differences between splenic and peritoneal B-1 cells, we re-examined
the ability of these subsets to proliferate when BCR is cross-linked with anti-IgM. As shown
in Fig. 1A, FACS sorted peritoneal B-1a and B-1b B cells failed to proliferate while B-2 cells
responded well to BCR cross-linking. Both subsets responded to LPS and CD40 stimulation
(data not shown). Similarly, sort purified splenic B-1 cells from C57BL/6 mice behaved like
the peritoneal B-1 cells and do not proliferate in response to anti-IgM stimulation (Fig. 1B).
Splenic B-1 cells obtained from VH12 transgenic mice also behaved like those from a wild
type strain and were unresponsive to BCR signals (Fig. 1C). B-1 cell response to other
stimulants such as LPS or anti-CD40 is comparable to B-2 cells suggesting that the defect in
B-1 cells is in the BCR initiated proliferative signals while the other pathways remain relatively
intact. Previous reports have indicated that splenic B-1 cells do not resemble peritoneal B-1
cells in all properties (Fischer et al., 2001; Frances et al., 2006; Tumang et al., 2004). However,
with respect to BCR induced growth response, both peritoneal and splenic B-1 cells were
similarly unresponsive. Also the transgenic splenic B-1 cells were similar to peritoneal B-1
cells from wild type mice in BCR responses.
Splenic B-1 cells are defective in BCR and CD19 induced Ca2+ mobilization
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It has been previously established that CD5 expression on B-1 cell surface confers their inherent
hypo-responsiveness to BCR signaling and lack of CD5 on peritoneal B-1 cells (CD5−/−) can
restore the BCR responsiveness (Bikah et al., 1996). The fact that both B-1a (CD5+) and B-1b
(CD5−) subtypes are deficient in anti-IgM induced proliferation indicates that apart from CD5,
BCR signaling in B-1 cells may be regulated by some other cell surface molecule (Fig. 1A)
(Sen et al., 2002). In this context, Sen et al. demonstrated that co-cross-linking of CD19 and
BCR induces a synergistic increase in Ca2+ response and that both peritoneal B-1a and B-1b
cells are deficient in a synergistic response in comparison to splenic B-2 cells. Recently,
peritoneal B-2 cells were reported to be less responsive than splenic B-2 (Hastings et al.,
2006). Therefore, we determined if the peritoneal B-1 cell response to BCR and CD19 crosslinking is less when compared to peritoneal B-2 response. Essentially three different peritoneal
B cell subsets (B-2, B-1a, B-1b) in the same tube were tested for calcium mobilization by using
B220, Mac-1 and CD5 markers to electronically gate the various B cell populations. We chose
a concentration of anti-IgM (◆) which on its own induces a low Ca2+ response in peritoneal
B-2 cells (Fig. 2A). In the peritoneal B-2 cells, this response was dramatically enhanced by
co-ligation with CD19 (▲) similar to the studies of Sen et al. (Sen et al., 2002) with B2 cells.
In both peritoneal B-1a (△) and B-1b (■) B cell populations, the Ca2+ response induced by
BCR and CD19 was significantly reduced in comparison to the peritoneal B-2 cell response.
Ligation of B cells with anti-CD19 alone causes a very low Ca2+ flux (⋄). Thus B-1 cell
responses to CD19-BCR co-ligation were reduced whether they were compared to splenic B-2
(Sen et al.) or to peritoneal B-2 cells (Fig. 2A) (Sen et al., 2002).
Because of the reported differences between splenic and peritoneal B cells we tested if splenic
B-1 cells behave similarly to peritoneal B-1 cells with respect to this defect in CD19 induced
Ca2+ response (Tumang et al., 2004). B-2 and B-1 cells from the same splenic cell population
were marked by B220 and CD43 so that their Ca2+ response can be tested under identical
stimulation conditions. Once again a low dose of biotinylated anti-IgM was used so that it
induced a very small calcium flux which was dramatically enhanced when IgM and CD19 were
co-crosslinked. The anti-CD19 antibody by itself had a minimal effect on the response. When
gated on B-1 population (B220+ CD43+) from wild type splenic cells; the synergistic response
obtained from BCR and CD19 co-cross-linking was again lower in magnitude (△) than that
from the gated B-2 population (B220+ CD43−) in the same sample analyzed (▲) (Fig. 2B).
The B-1 cells did not respond to anti-IgM (low dose) or anti-CD19 (optimal dose) when added
separately. Transgenic splenic B-1 cells from VH12 mice, like the wild type strain, mounted a
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Ca2+ response to BCR-CD19 co-cross-linking that was comparably lower than B-2 cells from
the same pool of cells (Fig. 2C).
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In order to confirm that the splenic and peritoneal B-1 cells are deficient in mobilizing receptor
mediated Ca2+ and not in non-receptor evoked Ca2+ flux; we stimulated splenic cells with
thapsigargin. Thapsigargin is an inhibitor of sarcoplasmic endoplasmic reticulum calciumATPase (SERCA), a channel which functions to reuptake Ca2+ into the endoplasmic reticulum
(ER) (Thastrup et al., 1990). Thapsigargin depletes ER Ca2+ stores independent of IP3
generation. Fig. 2D indicates that splenic B-1 cells, like splenic B-2 cells, are equally capable
of mobilizing Ca2+ when treated with thapsigargin. Calcium ionophores such as Ionomycin
and A23187 facilitate the direct transport of Ca2+ across the plasma membrane (Klaus et al.,
1985). When peritoneal B cells were treated with 1 μM Ionomycin a similar calcium response
was elicited in all subsets of peritoneal B cells (Fig. 2E). The differences between the three
subpopulations were small and not statistically significant. Therefore, the Ca2+ flux defect that
we observe in Figure 2 (A,B,C) from B-1 cells is specific to that generated via the BCR and
CD19.
CD5 does not regulate CD19 induced calcium responses
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Since CD5 has been shown to affect Ca2+ responses induced by BCR alone, we questioned if
CD5 expression affected the BCR + CD19 induced response (Tarakhovsky et al., 1994). When
gated on the B220+ Mac-1+ B-1 cells, the response from the CD5−/−peritoneal B-1 cells was
of similar magnitude to that observed from the wild type cells (Fig. 2F). Thus the BCR + CD19
induced Ca2+ response of B-1 cells from wild type or CD5−/− mice was identical suggesting
that the CD19 response is not regulated by CD5.
BCR and CD19 induced intracellular Ca2+ release in B-1 and B-2 subsets is similar and is
PI3K dependent
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The Ca2+ flux detected upon BCR and CD19 co-cross-linking in splenic B cells is constituted
by intra- and extra-cellular components, which are almost not exclusive. BCR activation leads
to phosphorylation of CD19 which allows recruitment of PI3K to CD19 (Y482, Y513) and
subsequent activation of PI3K leads to generation of PI(3,4,5)P3 from PI(4,5)P2 (Wang et al.,
2002). PIP3 is utilized by Btk to activate PLCγ which now generates second messenger
molecules DAG and IP3 (Fujimoto et al., 2001). IP3 upon binding to IP3 receptors on ER
membrane facilitates extrusion of Ca2+ from ER stores which generates the initial cytosolic
pool of Ca2+. Depletion of ER Ca2+ stores triggers opening of TRPC (C-type transient receptor
potential) class of ion channels (Ambudkar et al., 2007). The activated TRPCs allow further
influx of Ca2+ from extracellular sources (Inada et al., 2006). In order to examine if the defect
in CD19 induced Ca2+ is in the intra- or extra-cellular calcium mobilization, the response of
B cell subsets in the absence of extracellular supply of Ca2+ was examined. Splenic B cells
from BL/6 mice were resuspended in EGTA and stimulated via their BCR and CD19. Fig. 3A
recapitulates the difference between B-1 and B-2 cells in calcium containing medium. Addition
of EGTA not only greatly reduces the overall Ca2+ response but the difference in magnitude
of response between B-1 and B-2 is minimal (Fig. 3B). This similarity in the intracellular
Ca2+ release upon anti-IgM and anti-CD19 stimulation of B-1 and B-2 subsets is evident in
the VH12 negative littermate (Fig. 3C) as well as VH12 transgenic mice (Fig. 3D) suggesting
that the major reason for defective BCR + CD19 induced response is in the influx of
extracellular Ca2+ into the cell.
Majority of the Ca2+ flux seen in B-2 cells upon BCR + CD19 stimulation is through PI3K
activity. In order to assess if this is the case in B-1 cells; splenic B cells were pre-incubated at
room temperature for 25 min with a PI3K inhibitor, wortmannin (Fig. 4). The Ca2+ response

Mol Immunol. Author manuscript; available in PMC 2010 August 1.

Dasu et al.

Page 7

of B-2 cells was significantly reduced by wortmannin. The small response of splenic B-1 cells
to anti-IgM and anti-CD19 was also reduced by wortmannin.
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CD19 dependent Akt activation is deficient in splenic B-1 cells
Phosphorylation of a serine/threonine protein kinase Akt is a downstream event in PI3K
signaling pathway (Otero et al., 2001). Akt activation serves as a survival and proliferative
mechanism by its ability to activate the NFκB pathway. BCR stimulation leads to
phosphorylation of Akt in B-2 but not in B-1 cells (Wong et al., 2002). CD19 by itself is capable
of activating the serine/threonine protein kinase Akt in primary splenic B cells and is necessary
to enhance the Akt activation following cross-linking of mIgM (Otero et al., 2001). We have
found that in B-2 cells anti-IgM induced pAkt (S473) is further upregulated slightly when cocrosslinked with anti-CD19 (Fig. 5). Interestingly, in VH12 transgenic B-1 cells, pAkt induced
by optimal dose of anti-IgM was reduced. Neither BCR ligation alone nor BCR and CD19
coligation failed to induce any detectable phosphorylation of Akt. This may explain why there
is a low proliferative response to BCR cross-linking.
JNK activation is lower in splenic B-1 cells
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BCR stimulation leads to activation of stress-activated protein kinase (SAPK/JNK). BCR
induced pJNK is greater and occurs quicker in B-2 than in B-1 cells (O’Rourke et al., 1998).
Phosphorylation of CD19 (Y391, Y421) leads to recruitment of Vav and culminates in
activation of JNK (Wang et al., 2002). Co-cross-linking of BCR and CD19 on splenic B-2 cells
leads to further enhancement of BCR induced phosphorylation of JNK (Tooze et al., 1997).
JNK exists in two isoforms, p54 and p46 as shown in the immunoblot. We are showing only
the phosphorylation of p54 isoform since phosphorylation of p46 isoform was minimal under
these conditions. In our system, we demonstrate that the level of pJNK in splenic B-2 cells
upon anti-IgM and anti-CD19 co-cross-linking is higher than with the either antibody alone.
In the VH12 splenic B cells, the JNK phosphorylation induced by BCR ligation was less than
in the B-2 cells and this response was not enhanced by co-ligation of BCR and CD19 at the
time point tested (Fig. 6). Stimulation with PMA indicates that the B-1 cells are responsive to
other non-BCR induced JNK activation. This indicates that splenic B-1 cells are deficient in
another CD19 dependent function, i.e. JNK activation.
Peritoneal B-1 cells express pLyn constitutively
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Lyn, a src family tyrosine kinase member, is known to regulate B cell activation in both positive
and negative manner (Xu et al., 2005). BCR induced Lyn phosphorylation is essential for CD19
activation. To test the status of Lyn in peritoneal B-1 and splenic B-2 cells, we
immunoprecipitated Lyn from lysates obtained from macrophage and T cell-depleted
peritoneal B-1 cells and splenic B-2 cells. When they were probed with anti-p-SFK antibody
that detects activated form of Lyn, we observed that Lyn is constitutively phosphorylated in
peritoneal B-1 cells as compared to a lower level of pLyn in resting splenic B-2 cells (Fig. 7A).
There was no significant increase in total Lyn in B-1 cells compared to B-2 cells. We, therefore,
considered the possibility that Lyn plays a negative role in the context of peritoneal B-1 cells
by its ability to phosphorylate inhibitory receptors, enzymes and adaptor molecules.
The negative regulation of Lyn in B lymphocytes has been shown to involve recruitment of
SHP-1 (Cornall et al., 1998). In order to determine if the increased levels of pLyn might be
negatively regulating the BCR signal in B-1 cells via SHP-1, we first determined the level of
total SHP-1 in lysates obtained from peritoneal B-1 cells before or after stimulation via BCR
and CD19. As shown in Fig 7B, the total level of SHP-1 protein expressed in the peritoneal
B-1 cells was not very different from the littermate splenic B-2 cells indicating that the
cytoplasmic SHP-1 available for the phosphatase function of the enzyme is similar in B-1 and
B-2 cells. The SHP-1 levels were not altered by BCR or CD19 stimulation but were always
Mol Immunol. Author manuscript; available in PMC 2010 August 1.
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slightly lower upon co-cross-linking of CD19 and BCR, a phenomenon observed in both B-1
and B-2 cells. However, this does not necessarily mean all of the available SHP-1 is associated
with pLyn. Lyn has been previously shown to bind the –SH2 domain of SHP-1 in activated B
cells (Somani et al., 2001). When tested for enhanced Lyn/SHP-1 association in B cells, the
lysates immunoprecipitated with anti-Lyn did not show differences in the association of SHP-1
in B-1 and B-2 cells suggesting that SHP-1 may not have a role in the negative regulatory
function of Lyn under these experimental conditions (Fig. 7C). Consistent with this we found
that B-1 cells from SHP-1 deficient motheaten mice exhibited similar defects in BCR + CD19
induced Ca2+ response when compared to B-2 cells from the normal littermate (Fig. 7D).
Moreover, the splenic B-2 cell responses from motheaten mice are significantly better than
those observed in the littermate control mice as has been previously reported (Fig. 7E). Recently
Pao et al. have demonstrated that upon cross-linking BCR only, splenic B-1 cells (B220lo
CD5+) with a B-cell specific deletion of ptpn6 gene exhibit greater increase in intracellular
Ca2+ concentration than B-1 cells in littermate controls. Thus, they propose SHP-1 to be a
negative regulator of BCR evoked Ca2+ responses in splenic and peritoneal CD5+ B-1a B cells
(Pao et al., 2007).
Blocking Lyn activation partially rescues BCR and CD19 induced signaling defect in B-1 cells

NIH-PA Author Manuscript
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We tested the putative negative regulatory role of pLyn in B-1 cells by determining if inhibition
of Lyn can enable B-1 cells to overcome the BCR/CD19 signaling defects. Accordingly, we
treated B-1 cells with a potent and selective src family tyrosine kinase (SFK) inhibitor,
pyrazolopyrimidine PP1 (Hanke et al., 1996). Peritoneal cells from C57BL/6 mice were loaded
with Indo-1, treated with anti-IgM and anti-CD19 and stained for B-1 specific markers (B220
and Mac-1). These cells were pre-incubated with various doses of PP1 at room temperature
for 20 min, warmed to 37°C for 2 min and stimulated with avidin after taking a 30 s baseline
(Fig. 8A). The B-1 cells that were not treated with PP1 showed a modest BCR + CD19 induced
Ca2+ response (■), as shown in previous figures. Pre-treatment of cells with PP1 enabled the
B-1 cells to overcome this Ca2+ defect and allowed them to flux cellular Ca2+ to a greater
magnitude (△, ○). This enhancement of Ca2+ response was dose-dependent. Addition of PP1
alone or vehicle control (DMSO equivalent) did not elicit any measurable Ca2+ changes over
the baseline (data not shown). Similar results were obtained with splenic B-1 cells (Fig. 8B).
In order to test if this phenomenon of enhancement can be exhibited even by the CD5− B-1b
subset, we have included the CD5 marker along with B220 and Mac-1 to monitor the generation
of Ca2+ flux in all the three sub-populations of peritoneal B cells. Interestingly, pre-treatment
of peritoneal cells with the SFK inhibitor PP1 enabled both B-1a and B-1b B cells to better
elicit Ca2+ response to BCR + CD19 co-cross-linking (Fig. 8C). This indicates that there is a
certain amount of pLyn required for B-1 cells to generate Ca2+ from the ER stores. If there are
greater levels of pLyn than an optimal quantity, Lyn may potentially recruit negative regulators
of B cell signaling and down modulate the Ca2+ response.
In order to investigate if PP1 induced restoration of calcium response can translate into recovery
of a functional response, peritoneal B-1 cells were stimulated with anti-IgM in combination
with increasing doses of PP1 for 48 hours in IF-12 medium. Fig. 8D shows that addition of
PP1 to anti-IgM stimulated peritoneal B-1 cells enabled them to proliferate significantly to the
BCR signal. Fig. 8E shows that the BCR induced proliferation response of splenic B-1 cells is
also enhanced by PP1. As shown in Fig. 8F, PP1 indeed inhibited Lyn phosphorylation in
unstimulated cells and in BCR+CD19 stimulated B-1 cells. Similar results were obtained with
PP2, another SFK inhibitor both in Ca2+ experiments (Fig. 9A) and in proliferation response
(Fig. 9B). Thus the high pLyn levels seen in the B-1 cells not only negatively regulate the initial
signaling events such as Ca2+ generation (Fig. 8A), but also the proliferative response (Fig.
8D). Higher doses of PP1 and PP2 inhibited the BCR induced proliferation responses consistent
with the need for optimal levels of Lyn for B cell activation.
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Numerous reports have firmly established the positive signaling role of CD19 in aiding BCR
induced responses both in vitro and in vivo. However, B cell activation has not been addressed
in the context of CD19 function in B-1 B lymphocytes. We have demonstrated earlier that there
is a deficiency in CD19 induced intracellular signals in the peritoneal B-1 cells (Sen et al.,
2002). The current study examines the importance of CD19 in regulating BCR signaling defect
in various B-1 cell subpopulations from normal wild type mice and in transgenic mice.
Rothstein and colleagues have shown that splenic B-1 cells differ from peritoneal B-1 cells in
certain functional properties and transcriptional programs (Fischer et al., 2001; Tumang et al.,
2004). But, B-1 cells obtained from both these distinct anatomical locations are similar in one
major aspect of B cell activation: they are hyporesponsive to B cell receptor induced growth
signals. This result has enabled us to utilize splenic B-1 cells from wild type as well as VH12
transgenic mouse strains in order to understand the biochemical basis of BCR defect in B-1
cells (Arnold et al., 1994). We showed that B-1a and B-1b cells from peritoneum and spleen
and from wild type and transgenic mice fail to proliferate in response to BCR ligation and
exhibit reduced Ca2+ mobilization when BCR and CD19 are co-cross-linked. Many previous
studies have been performed with B-1 cells from various BCR transgenic mice. Our study is
unlike such reports in that it analyzes B-1 cells from various compartments in both normal and
transgenic mice making the results representative of most B-cell subpopulations.
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Our calcium mobilization experiments led to a very interesting finding that the defect lies in
the differential levels of Ca2+ influx in B-1 and B-2 cells whereas the intracellular release is
similar between the two populations (Fig. 3). This could possibly be due to comparably lowered
activation status of the plasma membrane Ca2+ channels. STIM (stromal interaction molecule)
proteins residing in the ER act as sensors to Ca2+ depletion from the ER stores (Spassova et
al., 2006). Orai, the regulatory subunit of TRPC channels participates in the store-operated
Ca2+ entry (SOCE) process (Inada et al., 2006). Disruption in one of more members of the
TRPC channels has been shown to modulate the magnitude of Ca2+ flux in B cell line models
(Mori et al., 2002).
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B-1b (CD5−) subset of B-1 cells have been shown by Dal Porto et al to be almost equally
capable of mobilizing Ca2+ as do B-2 cells when triggered through the surface IgM (Dal Porto
et al., 2004). We, however, have found B-1b B cells behave like B-1a B cells in eliciting reduced
Ca2+ responses upon BCR and CD19 co-cross-linking when compared to splenic or peritoneal
B-2 cells. Our findings about differences in B-1b and B-2 cells were performed in the same
pool of cells in the same tube ruling out any artifacts. The difference between our results and
those of Dal Porto et al. could be due to the fact that BCR response may be normal while CD19
response is defective. However, we find that BCR response is also defective in B-1b B cells.
It was unclear how the assays were performed by Dal Porto et al. as they appear to compare
peritoneal B-1b to splenic B-2 cells and the calcium profiles do not provide any information
about the magnitude of response to cross-linking BCR alone. In our case, we find that both
peritoneal B-1a (CD5+) and B-1b (CD5−) B cells cannot respond to anti-IgM initiated
proliferative signals as well as peritoneal B-2 cells (Fig. 1). Additionally, these subsets of B-1
cells generate Ca2+ flux in response to BCR and CD19 co-cross-linking, the magnitude of

Consistent with the notion that CD19-mediated signals are deficient in B-1 cells, BCR + CD19
induced pAkt was lower in B-1 cells which may have a role in the low response of B-1 cells
to IgM induced in vitro proliferative signals (Fig. 5). Wong et al. have reported that B-1 cells
are defective in BCR dependent MAPK activation, in particular ERK (Wong et al., 2002). We
find that B-1 cells are also defective in BCR and CD19 induced JNK activation, a key MAPK
enzyme involved in cell survival and proliferation thus possibly contributing to their reduced
proliferative ability to IgM stimulation (Fig. 6) (Gururajan et al., 2005).
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which is drastically lower than either splenic or peritoneal B-2 cells when assayed in the same
tube. Hence, CD5 alone may be insufficient to regulate CD19 + BCR responses in B-1 cells
(Fig. 2). This is further strengthened by the observation that the BCR-CD19 response of B-1
cells is defective even in CD5−/− mice (Fig. 2F). Importantly, both splenic B-1 and peritoneal
B-1 B cells were found to be similar in their defective response to BCR-CD19 cross-linking.
This also indicates that the B-1 cells are deficient in CD19 initiated positive signaling events
irrespective of their location. Previous studies suggested that CD5 dependent Lck activation
may have a role in the reduced responses of B-1a cells but other investigators failed to find
Lck expression in B-1 cells (Dal Porto et al., 2004; Frances et al., 2005).
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Receptor proximal signaling events in B cell activation are highly crucial to determine the
overall effector function of the B cell. Lyn forms an important link in BCR dependent CD19
activation and lyn−/− mice exhibit hyper-responsive phenotype culminating in auto-immunity
(Chan et al., 1997). It has recently been discovered that Lyn phosphorylation can lead to dual
effects of either upregulating or downmodulating B cell signaling (Xu et al., 2005). Since we
observed high levels of pLyn in splenic and peritoneal B-1 cells both in resting as well as BCR
+ CD19 activated state in otherwise hyporesponsive B-1 cells; it is possible that pLyn
phosphorylates the ITIM (immunoreceptor tyrosine-based inhibitory motif) of inhibitory
receptors on B cell surface to a greater degree than activating proteins with ITAM
(immunoreceptor tyrosine-based activation motif) domains. Alternatively, Lyn may directly
phosphorylate phosphatases such as SHP-1, SHIP-1 and induce their activation, which in turn
may inhibit BCR-induced downstream signaling intermediates.
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Previous studies by Hashimoto et al. demonstrate that BCR cross-linking induced
depolarization leading to a decrease in store-operated Ca2+ (SOC) influx and inhibition of
store-operated calcium channels in DT40 B cells. This inhibition of SOC was abolished in
Lyn-deficient but not in Btk, Syk, or SHIP-deficient cells indicating that Lyn plays a role in
the inhibition of calcium influx (Hashimoto et al., 2001). This is consistent with our observation
that Lyn activity is increased in B-1 cells and that they exhibit a defect in calcium infux upon
BCR-CD19 cross-linking. Other proteins such as CD22, CD72, FcγRIIb, SHIP-1 and SHP-1
have also been implicated in regulating BCR initiated signaling pathways (Cornall et al.,
1999; Nadler et al., 1997a). All these molecules are potential substrates for the hyper active
Lyn in B-1 cells. The negative regulatory role of CD22 in BCR mediated calcium signaling
has already been demonstrated in B cell lines (Nadler et al., 1997b). Lyn has been shown to
be required for CD22 and CD72 inhibition (Smith, 1998) (Adachi et al., 2001). Lajaunias et
al. found that CD22 does not regulate BCR responses in B-1 cells (Lajaunias et al., 2002).
However, they did not look at the effect of CD22 on CD19 signaling. Although FcγRIIb is a
well known negative regulator of BCR signaling, hyporesponsiveness of B-1 cells to BCR is
thought to be independent of this receptor since similar results are obtained with intact and F
(ab′)2 fragments of anti-BCR antibodies. Its role in CD19 signaling has to be investigated using
F(ab′)2 fragments of anti-CD19 antibodies. A recently described novel B cell restricted lectin
protein, Siglec-G, acts as an inhibitory receptor by diminishing α-IgM evoked Ca2+ response
in B-1 B cells (Hoffmann et al., 2007). The mechanism of inhibition, however, remains to be
determined. An analysis of the synergistic effect of BCR + CD19 co-cross-linking in B-1 vs.
B-2 B cells in siglec−/− mice may lead to a better understanding of the inhibitory mechanism.
In our earlier studies we found that CD19 phosphorylation was similar in B-1 and B-2 cells
stimulated via BCR at early time points but was less at late time points (30 minutes) (Sen et
al., 2002). In this study we found an elevation in Lyn activity in B-1 cells even without any
stimulation even though we did not examine Lyn activity at late time points after BCR
signaling. The decrease in CD19 phosphorylation at late time points could be due to Lyn
dependent activation of a phosphatase (whose identity is not known at this time) that
dephosphorylates CD19 in B-1 but not B-2 cells. Alternatively, a negative regulator in B-1
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cells is competing with CD19 for Lyn activity at later time points. Recently Pao et al. have
demonstrated by using conditional B cell specific ptpn6 knock out mice that upon cross-linking
BCR only, splenic B-1 cells (B220lo CD5+) exhibit greater increase in intracellular Ca2+
concentration than B-1 cells in littermate controls. Thus, they propose SHP-1 to be a negative
regulator of BCR evoked Ca2+ responses in splenic and peritoneal CD5+ B-1a B cells (Pao et
al., 2007).
Blocking Lyn activity by synthetic inhibitors PP1 or PP2 upregulated the anti-IgM induced
proliferative response in B-1a and B-1b peritoneal B cells. At the same time, it also enhanced
the ability of B-1 cells to flux Ca2+ to BCR + CD19 signaling. It, therefore, confirms the finding
that high levels of pLyn in B-1 cells have a critical role in the unresponsiveness of this subset
of B cells to BCR cross-linking. Reducing the phosphorylated levels of Lyn to a certain extent
is able to restore the response in B-1 cells. Total inhibition of pLyn is also not desirable since
Lyn activity is required for positive downstream signaling events in the B cell. Accordingly,
higher doses of PP1/2 are inhibitory to B-1 cell function. Since the specificity of small molecule
inhibition to Lyn is not absolute, role of Lyn has to be further confirmed with other approaches.
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However, B-1 cells are known to be difficult to transfect. Presently, we are evaluating cell
permeable peptide inhibition to block Lyn in B-1 cells, a technique successfully used by
Mataraza et al. to demonstrate the importance of Cyclin D3 for B-1 cell proliferation (Mataraza
et al., 2006).
The similar role of CD19 signaling in B-1a and B-1b B cell activation found in this study does
not contradict the unique distribution and function of B-1a and B-1b B cells found in CD19
deficient and human CD19 transgenic mice as reported by Haas et al. (Haas et al., 2005). Thus
CD19 signaling may have distinct roles in the development of B-1a and B-1b B cells which
are thought to arise from distinct precursors in fetal liver and adult bone marrow (Dorshkind
and Montecino-Rodriguez, 2007). Once these cell lineages have been generated they may have
similar CD19 associated signaling pathways resulting in their hyporesponsiveness.
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Our findings contribute to a significant understanding of downstream signaling events that are
responsible for BCR defect in B-1 cells, cells that are highly cross-reactive to auto-antigens.
It still remains to be understood how such unresponsive B cells are capable of secreting
abundant levels of serum IgM in the absence of intentional immunization. This is particularly
intriguing because of the recent observations by Alugupalli et al. and Haas et al. that B-1b B
cells are respond vigorously in making antibody responses upon challenge with Borrelia
Hermsii and Streptococcus pneumoniae bacteria and that B-1b B cells are functional in the
absence of CD19 (Alugupalli et al., 2004; Haas et al., 2005). Our proliferation results indicate
that B-1a and B-1b B cells are equally capable of responding to LPS or T-dependent CD40
stimulation in vitro as do B-2 cells. This leads us to suggest that because of their auto-reactive
receptor expression, the BCR signaling per se is maintained in a state of ‘anergy’. When
activated via additional pathways, such as TLR and CD40, especially in the context of whole
bacteria, the B-1 cells are able to overcome the B cell receptor unresponsiveness, as suggested
by Alugupalli and Gerstein (Sindhava et al., manuscript in preparation) (Alugupalli and
Gerstein, 2005).
In summary, we have shown that part of the reason for apparent anergic state of B-1a, B-1b B
cells from spleen or peritoneum, or VH12 transgenic mice is due to a defect in CD19 signaling.
For the first time, we have shown that the defective CD19 and BCR signaling is due to a
constitutively high levels of activated Lyn and that the anergic state can be repaired by blocking
pLyn.
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Figure 1. Peritoneal and splenic B-1 cells are hyporesponsive to BCR mediated proliferation

(A) T cell-depleted splenic and FACS purified peritoneal B-1a and B-1b B cells from C57BL/
6 mice were cultured at a cell density of 2.0 × 105 cells/well with anti-IgM F (ab′)2 or antiCD40 for 48 hours with indicated mitogens. Shown are the mean proliferation + SE from
triplicate set of wells.
(B) FACS purified splenic B-1 (B220+ CD43+) and B-2 (B220+ CD43−) cells were plated at
2.5 × 105 cells/well, treated with the stimulants at the indicated concentrations, cultured for 48
hours and measured for proliferative response by 3[H] Thymidine incorporation. The graph
represents one of three independent assays.
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(C) T cell-depleted VH12 transgenic splenic B-1 cells and negative control littermates were
plated at a cell density of 2.5 × 105 cells/well and cultured for 48 hours as in (B). Graph
represents one of three independent assays. * indicates p < 0.01 when comparing B-1 and B-2
cell responses.
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Figure 2. BCR and CD19 induced Ca2+flux is defective in peritoneal B-1a, B-1b; and splenic B-1
cells

(A) Peritoneal cells (B220+) were gated on B-1a (Mac-1+, CD5+), B-1b (Mac-1+, CD5−) and
B-2 (Mac-1−, CD5−) cells to obtain Ca2+ flux upon 0.5 μg/ml biotinylated anti-IgM + 2 μg/ml
biotinylated anti-CD19 stimulation. Arrow indicates the time of addition of avidin to crosslink biotinylated anti-IgM and/or anti-CD19 antibodies. Graph represents mean of relative
Ca2+ concentration from triplicate analysis + SE. p < 0.05 when comparing responses of
peritoneal B-2 with B-1a or B-1b separately at each time point (seconds) indicated by the (*).
Data shown are from a representative experiment repeated thrice.
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(B) Splenic cells from C57BL/6 female mice were gated on B-1 (B220+ CD43+) and B-2
(B220+ CD43−) B cell subsets and the relative Ca2+ concentration plotted as a function of time.
p < 0.05 (*) compares the response from splenic B-2 and B-1 cells. Graphs are representation
of one of four independent experiments.
(C) Splenic cells from 4–6 month old VH12 transgenic mice were gated on B-1 and B-2 B cell
populations as in panel B above and the relative Ca2+ concentration from triplicate set of tubes
was plotted as a function of time. p value was < 0.01 (*) at the 75–200 second determinations.
The graph is a representative of more than 6 independent experiments.
(D) Non-receptor induced Ca2+ flux in B-1 and B-2 cells: Thapsigargin (1 μM) was added to
C57BL/6 mouse splenic cells 30 s after taking a baseline Ca2+ level (downward arrow).
Relative Ca2+ concentration evoked by thapsigargin in splenic cells gated on B-1 (B220+
CD43+) and B-2 (B220+ CD43−) as a function of time is plotted.
(E) Peritoneal cells from C57BL/6 mice were treated with 1 μM Ionomycin after obtaining the
30 sec baseline calcium concentration. Response shown was the effect of non-receptor
mediated generation of Ca2+ in the gated B-2, B-1b and B-1a sub-populations.
(F) Peritoneal cells from 3 month-old C57BL/6 (WT) or CD5−/− mice were gated on B-1
(B220+, Mac-1+) to obtain Ca2+ flux upon anti-IgM + anti-CD19 (both antibodies are
biotinylated) stimulation. Arrow indicates the time of addition of avidin to cross-link
biotinylated anti-IgM and anti-CD19 antibodies. Graph represents mean of relative Ca2+
concentration from triplicate analysis + SE. This is one of two independent experiments with
similar results.
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Figure 3. Effect of chelating extracellular calcium with EGTA on B cells stimulated with BCR and
CD19

(A and B) BCR and CD19 induced intracellular Ca2+ response appears to be similar in both
splenic B-1 and B-2 cells. C57BL/6 spleen cells were treated as in Fig. 2 and gated on splenic
B-1 (B220+ CD43+) and B-2 cells (B220+ CD43−) (Panel A). To obtain intracellular Ca2+ flux,
cells were resuspended in media containing 6 mM EGTA to chelate extracellular Ca2+ available
in the media (Panel B). Data shown is representative of one out of four independent
experiments. Graph is plotted with data of mean + SE from triplicate samples. p < 0.01
compares the B-2 cell response to the B-1 cell response at each time point indicated.
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(C and D) Biotinylated anti-IgM and biotinylated anti-CD19 co-cross-linking induced
intracellular Ca2+ flux in VH12 negative littermate control mice is similar in splenic B-1 and
B-2 cells. Splenic cells from VH12 negative littermate control mice (panel C) and transgenic
mice (panel D) were treated similar to wild type splenic cells as in (panel A) and intracellular
Ca2+ flux obtained as described above. Data plotted is mean + SE from triplicate samples. p <
0.01 comparing the response from B-2 cells with and without EGTA.
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Figure 4. The Ca2+flux generated by co-cross-linking BCR and CD19 on wild type splenic B cells
is PI3K dependent in both B-1 and B-2 subsets

Splenic B cells were treated with 0.5 μg/ml biotinylated anti-IgM and 2 μg/ml biotinylated
anti-CD19 and 10 μg/ml avidin was added to crosslink IgM and CD19. 25 nM wortmannin
was added at room temperature 25 min prior to analysis, as described in the Methods section.
p < 0.05 comparing the response from B-2 cells without and with wortmannin. This is a
representation of at least 3 independent experiments.
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Figure 5. BCR and CD19 signaling in transgenic splenic B-1 cells fails to activate Akt/PK-B

Purified splenic B cells from VH12 transgenic mice (VH12-Tg) and negative littermate controls
(VH12-NL) were stimulated with indicated antibodies for 15 min at 37°C and immunoblotted
for pAkt (at S473). Anti-IgM indicates the antibody without biotin and is used at 50 μg/ml.
Anti-μ~bio and anti-CD19~bio indicate biotin conjugated antibodies and are respectively used
at 0.5 and 2.0 μg/ml. 10 μg/ml avidin is used to cross-link IgM and CD19. This is a
representative of at least 3 independent experiments.
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Figure 6. Splenic B-1 cells fail to induce pJNK when stimulated via BCR and CD19

Purified splenic B cells from the two mouse strains were stimulated for 15 min at 37°C, lysed
and immunoblotted for pJNK and JNK1 as loading control. Immunoblot represents one of 3
independent stimulations. Anti-IgM, anti-μ~bio and anti-CD19~bio and avidin are used as
explained in legend to Fig 5.
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Figure 7. Peritoneal B-1 cells express high pLyn levels

(A) Peritoneal B-1 and splenic B-2 cells from C57BL/6 mice were resuspended in serum free
IF-12, rested for 30 min at 37°C and immunoprecipitated with anti-Lyn antibody and probed
for pSFK and Lyn.
(B) Peritoneal B-1 and splenic B-2 cells from wild type C57BL/6 mice were stimulated with
biotinylated anti-IgM and/or anti-CD19 + avidin and treated as in panel A above to obtain
whole cell lysates and immunoblotted for detection SHP-1 (~60 kDa), membrane was stripped
and re-probed for actin as gel loading control.
(C) Whole cell lysates obtained from similar treatment as in panel A were immuno-precipitated
with anti-Lyn antibody. The blot was probed for SHP-1, stripped and reprobed for Lyn to
correct for gel loading.
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(D and E) CD5-SHP-1 association is important for the negative regulatory role of CD5 in B-1
B cells: Total splenocytes from 3–4 week old viable motheaten (me/mev) and negative
littermate control mice were treated similar to the splenocytes from wild type C57BL/6 mice
in Fig. 2B. Duplicate set of cell suspensions stained independently for B-1 (B220+ CD43+)
and B-2 (B220+ CD43−) B cells were stimulated with avidin after 30 second relative calcium
concentration baseline determination. This is one of three independent experiments. The
responses from motheaten B-1 cells are shown in panel D and those from B-2 in motheaten
compared to littermate control mice in panel E.
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Figure 8. PP1 restores the BCR + CD19 signaling defect in B-1 cells

NIH-PA Author Manuscript

(A) Peritoneal cells were loaded with Indo-1 and stained with α-B220 and α-Mac-1/CD11b as
described in the Methods, treated with biotinylated anti-IgM and biotinylated anti-CD19; preincubated with PP1 at room temperature for 20 min prior to obtaining the 30 sec baseline.
Avidin was added as indicated by the arrow. Graph represents one of three independent
measurements.
(B) C57BL/6 splenocytes were Indo-1 loaded, stained with anti-B220~PE and antiCD43~FITC, incubated with biotinylated anti-IgM F(ab′)2 and biotinylated anti-CD19, pretreated with varying doses of PP1 for 20 min at room temperature, cell suspension warmed to
37°C, activated with avidin and calcium response monitored for 5 min. Shown were the
responses of the gated splenic B-1 (B220+ CD43+) B cells at two doses of PP1 (μM).
(C) Cells from peritoneal lavage were treated as in (A), stained with α-B220~CY, α-Mac-1~PE,
α-CD5~FITC, stimulated with biotinylated anti-IgM and biotinylated anti-CD19; pre-treated
with PP1 at room temperature for 20 min prior to determining the 30 sec baseline calcium
levels. Avidin was added as indicated by the arrow. Graph depicts the responses from gated
B-1a (B220+ Mac-1+ CD5+) and B-1b (B220+ Mac-1+ CD5−) sub-populations.
(D) Peritoneal B-1 and VH12 transgenic splenic B cells (panel E) were treated with 50 μg/ml
anti-IgM F (ab′)2 for 48 h in IF-12. The proliferative counts were determined as described in
the Methods. Plot represents one of three independent in vitro proliferation assays. p < 0.005
compares the cpm at each of the PP1 doses to the 0 PP1 (μM) group i.e. anti-IgM alone group.
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(F) Peritoneal B-1 cells were incubated with 2 μM PP1 for 30 min at 37°C. Cells were then
treated with biotinylated antibodies to IgM and CD19 and stimulated with avidin for 10 min.
The whole cell lysates were probed for pLyn (Y507), membrane was stripped and reprobed
for total Lyn protein as loading control.
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Figure 9. Inhibition of SFKs by PP2 partially overcomes BCR + CD19 signaling defect in B-1 cells

(A) Transgenic splenic B cells were treated similar to that in Fig. 8B. Cells were pre-treated
with different doses of PP2 (μM) and the calcium response to BCR + CD19 co-cross-linking
shown on the gated splenic B-1 cells.
(B) 2.5 × 105 VH12 transgenic splenic B-1 cells (T-cell depleted) were cultured for 48 hours
in an in vitro proliferation assay. Cells were incubated at 37°C with anti-IgM and different
concentrations of the pharmacological inhibitor PP2. Shown is a representative graph from one
of two independent experiments.
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